Kerry-Anne Rye And NotLipide

List of bibliographic references

Number of relevant bibliographic references: 7.

Ident.	Authors (with country if any)	Title
000E55	Roeland Huijgen [Pays-Bas] ; S. Matthijs Boekholdt [Pays-Bas] ; Benoit J. Arsenault [Pays-Bas] ; WEIHANG BAO [États-Unis] ; Jean-Michel Davaine [France] ; Fatiha Tabet [Australie] ; Francine Petrides [Australie] ; Kerry-Anne Rye [Australie] ; David A. Demicco [États-Unis] ; Philip J. Barter [Australie] ; John J. P. Kastelein [Pays-Bas] ; Gilles Lambert [France, Australie]	Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial: A Nested Case-Control Study
001931	Fatiha Tabet [Australie] ; Gilles Lambert [Australie, France] ; Luisa F. Cuesta Torres [Australie] ; LIMING HOU [Australie] ; Irene Sotirchos [Australie] ; Rhian M. Touyz [Canada] ; Alicia J. Jenkins [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie]	Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages
001F69	Fatiha Tabet [Australie] ; Alan T. Remaley [États-Unis] ; Aude I. Segaliny [Australie] ; Jonathan Millet [Australie] ; LING YAN [Australie] ; Shirley Nakhla [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [Australie] ; Gilles Lambert [France]	The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro
002203	Estelle Nobecourt [Australie] ; Fatiha Tabet [Australie] ; Gilles Lambert [Australie] ; Rajesh Puranik [Australie] ; SHISAN BAO [Australie] ; LING YAN [Australie] ; Michael J. Davies [Australie] ; Bronwyn E. Brown [Australie] ; Alicia J. Jenkins [France] ; Gregory J. Dusting [Australie] ; David J. Bonnet [Australie] ; Linda K. Curtiss [Australie] ; Philip J. Barter [Australie] ; Kerry-Anne Rye [États-Unis]	Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I
002931	Dick C. Chan [Australie] ; Gilles Lambert [Australie, France] ; P. Hugh R. Barrett [Australie] ; Kerry-Anne Rye [Australie] ; Esther M. M. Ooi [Australie] ; Gerald F. Watts [Australie]	Plasma Proprotein Convertase Subtilisin/ Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
002A97	Amal Zerrad-Saadi [France] ; Patrice Therond [France] ; Sandrine Chantepie [France] ; Martine Couturier [France] ; Kerry-Anne Rye [Australie] ; M. John Chapman [France] ; Anatol Kontush [France]	HDL3-Mediated Inactivation of LDL-Associated Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and HDL Particle Surface Lipid Rigidity: Relevance to Inflammation and Atherogenesis
002F98	Gilles Lambert [Australie, France] ; Nicolas Ancellin [France] ; Francesca Charlton [Australie] ; Daniel Comas [France] ; Julia Pilot [France] ; Anthony Keech [Australie] ; Sanjay Patel [Australie] ; David R. Sullivan [Australie] ; Jeffrey S. Cohn [Australie] ; Kerry-Anne Rye [Australie] ; Philip J. Batter [Australie]	Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024